Bacillus coagulans SNZ 1969®

Bacillus coagulans SNZ 1969® is a well-characterized and clinically studied probiotic strain

Bacillus coagulans SNZ 1969® is unique in the space of spore forming probiotic strains. It boasts an exceptional five-decade history of use, stability profile, research and genetic pedigree. Combined with Sanzyme’s experience in end-to-end production and decades of continuous technological improvement, SNZ 1969® is a reliable, long term choice for inclusion in probiotic formulations in food and supplements.

  • More than 30 clinical studies
  • 150+ Million doses in 40+ countries annually
SNZ1969

Global Acceptance and Regulatory Registrations

  • Bacillus Coagulans SNZ 1969® Notified vide GRN No. 597 as GRAS in the United States
  • Product License for SNZ 1969® assigned NPN No.80093760 by Health Canada for use in children and adults
  • Included in ANVISA Normative list (IN) No 28/2018 in Brazil. Approved for use as constituent in conventional foods and food supplements.
  • Probiotic claims notified to FSANZ in Australia and New Zealand

CLINICAL REFERENCE

  • Efficacy and Safety of Probiotic Bacillus coagulans - SNZ 1969® in Gastrointestinal Discomfort: A Randomized, Placebo-Controlled Study.

    Soman R.J., Singh K., Swamy M.V. International Journal of Health Sciences and Research, 2022. Vol.12; Issue: 3

  • Evaluation of efficacy and safety of Bacillus coagulans SNZ 1969® supplementation for irritable bowel syndrome: a randomized, double-blind, placebo-controlled study.

    Soman R.J., Gorantla S.C., Swamy M.V., International Journal of Basic & Clinical Pharmacology, 2022. Nov;11(6)

  • Spore-forming Bacillus coagulans SNZ 1969® improved intestinal motility and constipation perception mediated by microbial alterations in healthy adults with mild intermittent constipation: A randomized controlled trial.

    Kang S., Park M.Y., Brooks I., Lee J., Kim S. H., Kim J. Y., Oh B., Kim J.W., Kwon O. Food Research International 2021. 146, 110428

  • Safety and Efficacy of Bacillus coagulans SNZ 1969® Probiotic Supplementation in Reducing Infections in Malnourished Children: A Randomised, Double-blind, Placebo-controlled Study.

    Journal of Clinical and Diagnostic Research. 2024 Sep, Vol-18(9): FC01-FC06

  • Co-supplementation of Probiotic- Bacillus coagulans SNZ 1969® and Whey Protein Improves Amino Acid Absorption and Reduces the Incidence of Acne in Healthy Adults: A Randomized, Double-blind, Crossover Study

    Raunak J. Soman, Dhruv Soman, Venkata Kishan Pokuri

  • Comparative evaluation of probiotics on salivary mutans streptococci counts in Indian children

    Jindal G et al., European Archives of Paediatric Dentistry 2011; 12: Issue 4

  • Effect of freeze dried powdered probiotics on gingival status and plaque inhibition: A randomized, double-blind, parallel study.

    Contemp Clin Dent 2017; 8: 116-21.

  • The efficacy of probiotic Bacillus coagulans SNZ 1969® tablets in the treatment of recurrent Bacterial Vaginosis.

    International Journal of Probiotics and Prebiotics Vol. 12, No. 4, pp. 175-182, 2017

SNZ 1969® is hardy & versatile, natural spore forming probiotic
strain

Bacillus coagulans SNZ 1969® distinguishes itself as a resilient spore-forming probiotic strain, showcasing remarkable hardiness in various conditions. Its ability to construct a protective spore encased in a calcium-lipicolinic acid peptidoglycan complex ensures durability and survival until favorable circumstances arise. Remaining in a dormant state until conditions become conducive, it requires no refrigeration, offering practicality in storage and transportation. This resilience extends to enduring processing conditions and the gastrointestinal environment, ensuring its efficacy throughout its journey. With its robust nature, Bacillus coagulans opens doors to unlimited application opportunities, promising versatility and effectiveness across diverse products and industries.

bacillus-coagulans-SNZ-1969-versatile-application-scaled

Food

SNZ 1969® is thermal and process stable which makes it easy to formulate in a wide variety of conventional food formats, with health benefits. SNZ 1969® is stable in
wide variety of food products such as cereals, muesli, granola, chocolate, tea, coffee, health beverages, spreads, hard boiled candies, chews, gums, kombucha, juices,
puree, smoothies, protein bars, cereal bars, porridges, bread, cakes and more.

Supplements

Gummies, capsule, sachets, protein supplement, meal replacement and more

Application-Resource-Team-Sanzyme-Biologics

Application Support Services

Sanzyme Biologics’ application team has decades of experience in studying the incorporation and stability of probiotic strain in various matrixes and work closely to advise on the best possible approach. We’re here to assist you every step of the way, from initial ideation and prototyping to formulation, cell-count stability testing, production, marketing, and ongoing technical support.

Production in a Dedicated NSF Certified Facility

Sanzyme Biologics meticulously manages every step of probiotic production, maintaining stringent control over inputs and process parameters from flask cultivation to seed fermenters, through full-scale fermentation, and culminating in blending and spray drying. With extensive experience in spore-forming probiotics, our dedication to producing superior quality spores is unwavering. At Sanzyme Biologics, we have dedicated NSF certified plant specifically for the production of Bacillus coagulans, ensuring the highest standards of quality and safety in every step of the process.

Bacillus coagulans Sanzyme Biologics plants

PEDIGREE

Bacillus coagulans SNZ 1969® has been safely consumed by humans for over 50 years. This makes it one of the oldest, best studied and well characterized probiotics available in the market today. The strain initially isolated in Japan. In 1949, a Japanese physician, Dr. Nakayama isolated B. coagulans from green malt. This particular isolate was tested for its potential effects against diarrhea and constipation in adult as well as infants during 1964.

In 1972, at the request of Sankyo Corporation, the Japanese Ministry of Health and Welfare approved the use of this particular B. coagulans. Subsequently, in 1973, Sankyo Corporation (currently known as Daiichi Sankyo Co. Ltd) offered formulation and fermentation technology to Sanzyme Biologics Private Limited, India (earlier known as Uni Sankyo Ltd.). Since then, it has been marketed in India under the brand name “Sporlac” for the past 50 years and has been used as a probiotic with no adverse effects reported so far. In the year 2010 the strain was formally designated as SNZ 1969® by Sanzyme

Disclaimer: These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.